Thomas Jefferson University

Andrew Aplin

TitleProfessor
InstitutionThomas Jefferson University
DepartmentCancer Biology
Address233 S. 10th Street
Philadelphia PA 19107
Phone215-503-7296
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01GM067893     (APLIN, ANDREW E)Aug 1, 2004 - Mar 31, 2015
    NIH
    ADHESION AND ERK SIGNALING IN MELANOMA
    Role: Principal Investigator
    R01CA125103     (APLIN, ANDREW E)Aug 1, 2008 - May 31, 2014
    NIH
    B-RAF Regulation of the Cell Cycle in Melanoma
    Role: Principal Investigator
    R01CA160495     (APLIN, ANDREW ERIC)Jun 1, 2012 - Jul 31, 2023
    NIH
    FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
    Role: Principal Investigator
    R01CA182635     (APLIN, ANDREW ERIC)Jul 14, 2014 - May 31, 2025
    NIH
    Targeted therapies in cutaneous melanoma
    Role: Principal Investigator
    R01CA196278     (APLIN, ANDREW E)Jun 24, 2015 - May 31, 2021
    NIH
    Mutant BRAF-regulated transcription factors in melanoma progression
    Role: Principal Investigator
    T32CA236736     (LANGUINO, LUCIA R.)Sep 19, 2019 - Aug 31, 2024
    NIH
    Training Program in Cancer Biology
    Role: Co-Principal Investigator
    R01CA253977     (APLIN, ANDREW ERIC)Sep 1, 2020 - May 31, 2025
    NIH
    Mechanisms of uveal melanoma dormancy and targeted therapy tolerance
    Role: Principal Investigator
    R01CA257505     (GUTKIND, JORGE SILVIO)Apr 1, 2021 - Mar 31, 2026
    NIH
    Targeting Systems Vulnerabilities in the Gaq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma
    Role: Co-Principal Investigator
    R01CA256945     (APLIN, ANDREW ERIC)Jun 15, 2021 - May 31, 2026
    NIH
    Mechanisms of cell death in cutaneous melanoma
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chua V, Lopez-Anton M, Baqai U, Purwin TJ, Haj JI, Waltrich FJ, Trachtenberg I, Luo K, Tudi R, Jeon A, Han A, Chervoneva I, Davies MA, Aguirre-Ghiso JA, Sato T, Aplin AE. Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. Sci Signal. 2024 Jun 11; 17(840):eadn8376. PMID: 38861613.
      Citations:    
    2. Cavallo MR, Yo JC, Gallant KC, Cunanan CJ, Amirfallah A, Daniali M, Sanders AB, Aplin AE, Pribitkin EA, Hartsough EJ. Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma. Cell Death Discov. 2024 Apr 15; 10(1):175. PMID: 38622136.
      Citations:    
    3. Kadamb R, Anton ML, Purwin TJ, Chua V, Seeneevassen L, Teh J, Angela Nieto M, Sato T, Terai M, Roman SR, De Koning L, Zheng D, Aplin AE, Aguirre-Ghiso J. Lineage commitment pathways epigenetically oppose oncogenic Gaq/11-YAP signaling in dormant disseminated uveal melanoma. bioRxiv. 2024 Mar 08. PMID: 38496663.
      Citations:    
    4. Amaravadi R, Aplin A, Herlyn M, Holmen S, White R, Villanueva J. 20th Anniversary of the Society for Melanoma Research: Celebrating two decades of progress in melanoma research. Pigment Cell Melanoma Res. 2023 Nov; 36(6):562. PMID: 37903735.
      Citations:    
    5. Baqai U, Kurimchak AM, Trachtenberg I, Purwin TJ, Haj JI, Han A, Luo K, Pachon NF, Jeon A, Chua V, Davies MA, Gutkind JS, Benovic JL, Duncan JS, Aplin AE. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma. J Biol Chem. 2023 Nov 01; 105418. PMID: 37923138.
      Citations:    
    6. Rosenbaum SR, Caksa S, Stefanski CD, Trachtenberg IV, Wilson HP, Wilski NA, Ott CA, Purwin TJ, Haj JI, Pomante D, Kotas D, Chervoneva I, Capparelli C, Aplin AE. SOX10 loss sensitizes melanoma cells to cytokine-mediated inflammatory cell death. Mol Cancer Res. 2023 Oct 17. PMID: 37847239.
      Citations:    
    7. Arang N, Lubrano S, Ceribelli M, Rigiracciolo DC, Saddawi-Konefka R, Faraji F, Ramirez SI, Kim D, Tosto FA, Stevenson E, Zhou Y, Wang Z, Bogomolovas J, Molinolo AA, Swaney DL, Krogan NJ, Yang J, Coma S, Pachter JA, Aplin AE, Alessi DR, Thomas CJ, Gutkind JS. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Cell Rep Med. 2023 Oct 13; 101244. PMID: 37858338.
      Citations:    
    8. Filipescu D, Carcamo S, Agarwal A, Tung N, Humblin ?, Goldberg MS, Vyas NS, Beaumont KG, Demircioglu D, Sridhar S, Ghiraldini FG, Capparelli C, Aplin AE, Salmon H, Sebra R, Kamphorst AO, Merad M, Hasson D, Bernstein E. MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping. Nat Cell Biol. 2023 09; 25(9):1332-1345. PMID: 37605008.
      Citations:    
    9. Ott CA, Aplin AE. Targeting TEAD-ious resistance. Trends Cancer. 2023 Oct; 9(10):780-781. PMID: 37543514.
      Citations:    
    10. Purwin TJ, Caksa S, Sacan A, Capparelli C, Aplin AE. Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas. iScience. 2023 Sep 15; 26(9):107472. PMID: 37636077.
      Citations:    
    11. Han A, Mukha D, Chua V, Purwin TJ, Tiago M, Modasia B, Baqai U, Aumiller JL, Bechtel N, Hunter E, Danielson M, Terai M, Wedegaertner PB, Sato T, Landreville S, Davies MA, Kurtenbach S, Harbour JW, Schug ZT, Aplin AE. Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth. Cancers (Basel). 2023 Jun 30; 15(13). PMID: 37444561.
      Citations:    
    12. Glasheen MQ, Caksa S, Young AG, Wilski NA, Ott CA, Chervoneva I, Flaherty KT, Herlyn M, Xu X, Aplin AE, Capparelli C. Targeting up-regulated cIAP2 in SOX10-deficient drug tolerant melanoma. Mol Cancer Ther. 2023 Jun 21. PMID: 37343247.
      Citations:    
    13. Wilson HP, Aplin AE. Site matters in metastatic melanoma. Trends Cancer. 2023 Jun 17. PMID: 37331825.
      Citations:    
    14. Bhardwaj M, Lee JJ, Versace AM, Harper SL, Goldman AR, Crissey MAS, Jain V, Singh MP, Vernon M, Aplin AE, Lee S, Morita M, Winkler JD, Liu Q, Speicher DW, Amaravadi RK. Lysosomal lipid peroxidation regulates tumor immunity. J Clin Invest. 2023 Feb 16. PMID: 36795483.
      Citations:    
    15. Leader AE, Melillo RJ, Greene Q, Blanding-Godbolt J, Shimada A, Eischen CM, Aplin AE. Engaging community members in cancer research: an assessment of an NCI-designated cancer center. Cancer Causes Control. 2023 Jan 04. PMID: 36598655.
      Citations:    
    16. Lapadula D, Lam B, Terai M, Sugase T, Tanaka R, Farias E, Kadamb R, Lopez-Anton M, Heine CC, Modasia B, Aguirre-Ghiso JA, Aplin AE, Sato T, Benovic JL. IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression. Mol Cancer Ther. 2023 01 03; 22(1):63-74. PMID: 36223548.
      Citations:    
    17. Vernon M, Wilski NA, Kotas D, Cai W, Pomante D, Tiago M, Alnemri ES, Aplin AE. Raptinal Induces Gasdermin E-Dependent Pyroptosis in Na?ve and Therapy-Resistant Melanoma. Mol Cancer Res. 2022 12 02; 20(12):1811-1821. PMID: 36044013.
      Citations:    
    18. Krossa I, Strub T, Aplin AE, Ballotti R, Bertolotto C. Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? Cancers (Basel). 2022 Oct 05; 14(19). PMID: 36230787.
      Citations:    
    19. Cai W, Nguyen MQ, Wilski NA, Purwin TJ, Vernon M, Tiago M, Aplin AE. A Genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1/2 inhibitors in NRAS mutant melanoma. Cancer Res. 2022 Jun 03. PMID: 35657206.
      Citations:    
    20. Capparelli C, Aplin AE. Packing a Punch against PD-L1. Cancer Discov. 2022 Jun 02; 12(6):1413-1415. PMID: 35652219.
      Citations:    
    21. Caksa S, Baqai U, Aplin AE. The future of targeted kinase inhibitors in melanoma. Pharmacol Ther. 2022 May 02; 239:108200. PMID: 35513054.
      Citations:    
    22. Baqai U, Purwin TJ, Bechtel N, Chua V, Han A, Hartsough EJ, Kuznetsoff JN, Harbour JW, Aplin AE. Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma. Mol Cancer Res. 2022 Apr 15. PMID: 35426938.
      Citations:    
    23. Capparelli C, Purwin TJ, Glasheen M, Caksa S, Tiago M, Wilski N, Pomante D, Rosenbaum S, Nguyen MQ, Cai W, Franco-Barraza J, Zheng R, Kumar G, Chervoneva I, Shimada A, Rebecca VW, Snook AE, Hookim K, Xu X, Cukierman E, Herlyn M, Aplin AE. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nat Commun. 2022 03 16; 13(1):1381. PMID: 35296667.
      Citations:    
    24. Redding A, Aplin AE, Grabocka E. RAS-mediated tumor stress adaptation and the targeting opportunities it presents. Dis Model Mech. 2022 02 01; 15(2). PMID: 35147163.
      Citations:    
    25. Li X, Wang S, Mu W, Barry J, Han A, Carpenter RL, Jiang BH, Peiper SC, Mahoney MG, Aplin AE, Ren H, He J. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway. J Exp Clin Cancer Res. 2022 Jan 27; 41(1):41. PMID: 35086548.
      Citations:    
    26. Han A, Chua V, Baqai U, Purwin TJ, Bechtel N, Hunter E, Tiago M, Seifert E, Speicher DW, Schug ZT, Harbour JW, Aplin AE. Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma. Oncogene. 2022 02; 41(8):1129-1139. PMID: 35046531.
      Citations:    
    27. Rosenbaum SR, Tiago M, Caksa S, Capparelli C, Purwin TJ, Kumar G, Glasheen M, Pomante D, Kotas D, Chervoneva I, Aplin AE. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 2021 12 07; 37(10):110085. PMID: 34879275.
      Citations:    
    28. Terai M, Shimada A, Chervoneva I, Hulse L, Danielson M, Swensen J, Orloff M, Wedegaertner PB, Benovic JL, Aplin AE, Sato T. Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma. Cancers (Basel). 2021 Nov 17; 13(22). PMID: 34830903.
      Citations:    
    29. Leader AE, Aplin AE. From the Community to the Bench and Back Again: The Value of Patient and Community Engagement in Cancer Research. Cancer Discov. 2021 Sep; 11(9):2135-2138. PMID: 34479970.
      Citations:    
    30. Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Lubrano S, Gomes F, Arang N, Tiago M, Coma S, Wu X, Ford K, Day CP, Merlino G, Mali P, Pachter JA, Sato T, Aplin AE, Gutkind JS. Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma. Clin Cancer Res. 2021 Aug 15; 27(16):4664. PMID: 34389658.
      Citations:    
    31. Chua V, Han A, Bechtel N, Purwin TJ, Hunter E, Liao C, Harbour JW, Aplin AE. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma. Pigment Cell Melanoma Res. 2021 Aug 04. PMID: 34347929.
      Citations:    
    32. Han A, Schug ZT, Aplin AE. Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma. Trends Cancer. 2021 08; 7(8):671-681. PMID: 34127435.
      Citations:    
    33. Caksa S, Aplin AE. PROactively TACkling CDK4/6 therapy resistance. Nat Cancer. 2021 Apr; 2(4):372-373. PMID: 35121999.
      Citations:    
    34. Ohara M, Saito K, Kageyama K, Terai M, Cheng H, Aplin AE, Sato T. Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma. Cancers (Basel). 2021 Mar 04; 13(5). PMID: 33806615.
      Citations:    
    35. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, Harbour JW, Aplin AE. Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene. 2021 Mar; 40(9):1753. PMID: 33510355.
      Citations:    
    36. Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Gomes F, Arang N, Tiago M, Coma S, Lubrano S, Wu X, Ford K, Day CP, Merlino G, Mali P, Pachter JA, Sato T, Aplin AE, Gutkind JS. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma. Clin Cancer Res. 2021 Feb 10. PMID: 33568347.
      Citations:    
    37. Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Burd CE, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G. Melanoma models for the next generation of therapies. Cancer Cell. 2021 Feb 04. PMID: 33545064.
      Citations:    
    38. Rosenbaum SR, Wilski NA, Aplin AE. Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy. Cancer Discov. 2021 Jan 15. PMID: 33451983.
      Citations:    
    39. Aplin AE, Capparelli C. Combined SHPments: An Effective Therapeutic Strategy for MPNST. Cancer Res. 2021 Jan 15; 81(2):266-267. PMID: 33452215.
      Citations:    
    40. Han A, Purwin TJ, Aplin AE. Roles of the BAP1 tumor suppressor in cell metabolism. Cancer Res. 2021 Jan 14. PMID: 33446574.
      Citations:    
    41. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, William Harbour J, Aplin AE. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene. 2020 Nov 18. PMID: 33208912.
      Citations:    
    42. Chua V, Mattei J, Han A, Johnston L, LiPira K, Selig SM, Carvajal RD, Aplin AE, Patel SP. The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019). Clin Cancer Res. 2021 Jan 01; 27(1):28-33. PMID: 33060121.
      Citations:    
    43. Shen H, Wang GC, Li X, Ge X, Wang M, Shi ZM, Bhardwaj V, Wang ZX, Zinner RG, Peiper SC, Aplin AE, Jiang BH, He J. S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Oncogene. 2020 Dec; 39(49):7181-7195. PMID: 33037411.
      Citations:    
    44. Vido MJ, Rock J, Aplin AE. Role of serine 365 in BRAF V600E sensitivity to RAF inhibition. Pigment Cell Melanoma Res. 2020 Oct 01. PMID: 33000894.
      Citations:    
    45. Teh JLF, Erkes DA, Cheng PF, Tiago M, Wilski NA, Field CO, Chervoneva I, Levesque MP, Xu X, Dummer R, Aplin AE. Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. Cancer Immunol Res. 2020 Sep; 8(9):1114-1121. PMID: 32661093.
      Citations:    
    46. Sugase T, Lam BQ, Danielson M, Terai M, Aplin AE, Gutkind JS, Sato T. Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma. J Transl Med. 2020 May 20; 18(1):208. PMID: 32434572.
      Citations:    
    47. Teh JL, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso JA, Aplin AE. Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma. Mol Cancer Ther. 2020 May 19. PMID: 32430489.
      Citations:    
    48. Nguyen MQ, Teh JLF, Purwin TJ, Chervoneva I, Davies MA, Nathanson KL, Cheng PF, Levesque MP, Dummer R, Aplin AE. Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition. J Invest Dermatol. 2020 May 07. PMID: 32389536.
      Citations:    
    49. Tiago M, Capparelli C, Erkes DA, Purwin TJ, Heilman SA, Berger AC, Davies MA, Aplin AE. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma. Br J Cancer. 2020 Jan 14. PMID: 31932756.
      Citations:    
    50. Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020 Jan 14; 30(2):510-524.e6. PMID: 31940493.
      Citations:    
    51. Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2019 Dec 03. PMID: 31796433.
      Citations:    
    52. Gonçalves J, Emmons MF, Faião-Flores F, Aplin AE, Harbour JW, Licht JD, Wink MR, Smalley KSM. Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment Cell Melanoma Res. 2019 Nov 23. PMID: 31758842.
      Citations:    
    53. Erkes DA, Rosenbaum SR, Field CO, Chervoneva I, Villanueva J, Aplin AE. PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves BET inhibitor efficacy in melanoma. Pigment Cell Melanoma Res. 2019 Nov 06. PMID: 31696640.
      Citations:    
    54. Wilski NA, Del Casale C, Purwin TJ, Aplin AE, Snyder CM. Murine cytomegalovirus infection of melanoma lesions delays tumor growth by recruiting and re-polarizing monocytic phagocytes in the tumor. J Virol. 2019 Aug 02. PMID: 31375579.
      Citations:    
    55. Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE. In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma. Mol Cancer Ther. 2019 Jul 03. PMID: 31270153.
      Citations:    
    56. Petit V, Raymond J, Alberti C, Pouteaux M, Gallagher SJ, Nguyen MQ, Aplin AE, Delmas V, Larue L. C57BL/6 congenic mouse NRASQ61K melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo. Pigment Cell Melanoma Res. 2019 Jun 28. PMID: 31251472.
      Citations:    
    57. Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, He YY. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019 06 25; 10(1):2782. PMID: 31239444.
      Citations:    
    58. Erkes DA, Field CO, Capparelli C, Tiago M, Purwin TJ, Chervoneva I, Berger AC, Hartsough EJ, Villanueva J, Aplin AE. The next generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner. Pigment Cell Melanoma Res. 2019 May 07. PMID: 31063649.
      Citations:    
    59. Rogers C, Erkes DA, Nardone A, Aplin AE, Fernandes-Alnemri T, Alnemri ES. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat Commun. 2019 04 11; 10(1):1689. PMID: 30976076.
      Citations:    
    60. Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE. CADM1 is a TWIST1-regulated suppressor of invasion and survival. Cell Death Dis. 2019 Mar 25; 10(4):281. PMID: 30911007.
      Citations:    
    61. Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK. Inhibition of NF-?B-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma. Cancer Res. 2019 Mar 18. PMID: 30885979.
      Citations:    
    62. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med. 2019 Feb; 11(2). PMID: 30610113.
      Citations:    
    63. Nikbakht N, Tiago M, Erkes DA, Chervoneva I, Aplin AE. BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade. J Invest Dermatol. 2019 Jan 28. PMID: 30703359.
      Citations:    
    64. Lapadula D, Farias E, Randolph CE, Purwin T, McGrath D, Charpentier T, Zhang L, Wu S, Terai M, Sato T, Tall GG, Zhou N, Wedegaertner P, Aplin AE, Aguirre-Ghiso J, Benovic JL. Effects of Oncogenic Gaq and Ga11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res. 2018 Dec 19. PMID: 30567972.
      Citations:    
    65. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 Dec; 8(12):1654. PMID: 30510016.
      Citations:    
    66. Vido MJ, Le K, Hartsough EJ, Aplin AE. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep. 2018 Nov 06; 25(6):1501-1510.e3. PMID: 30404005.
      Citations:    
    67. Teh JL, Aplin AE. Arrested developments: CDK4/6 inhibitor resistance and alterations in the tumor immune microenvironment. Clin Cancer Res. 2018 Oct 04. PMID: 30287548.
      Citations:    
    68. Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res. 2018 Oct 01; 78(19):5680-5693. PMID: 30115691.
      Citations:    
    69. Teh JLF, Aplin AE. Playing the melanoma endgame. Clin Cancer Res. 2018 May 16. PMID: 29769205.
      Citations:    
    70. Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med. 2018 Apr 12. PMID: 29650805.
      Citations:    
    71. Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y. Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nat Commun. 2018 Apr 06; 9(1):1404. PMID: 29626208.
      Citations:    
    72. Chua V, Aplin AE. Novel therapeutic strategies and targets in advanced uveal melanoma. Curr Opin Oncol. 2018 Mar; 30(2):134-141. PMID: 29206651.
      Citations:    
    73. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms. Cancer Discov. 2018 Mar 01. PMID: 29496664.
      Citations:    
    74. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FC, Li J, Teh JL, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discov. 2018 Mar 01. PMID: 29496665.
      Citations:    
    75. Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nat Commun. 2018 01 02; 9(1):28. PMID: 29295999.
      Citations:    
    76. Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep. 2017 Nov 14; 21(7):1953-1967. PMID: 29141225.
      Citations:    
    77. Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo. Mol Cancer Ther. 2018 Jan; 17(1):84-95. PMID: 29133617.
      Citations:    
    78. Rosenbaum S, Aplin A. Running INTERFERONce on immunotherapy. Pigment Cell Melanoma Res. 2017 Oct 25. PMID: 29068157.
      Citations:    
    79. Aplin AE. "If you want to go far, go together". Pigment Cell Melanoma Res. 2017 Sep; 30(5):448. PMID: 28834183.
      Citations:    
    80. Sample A, Zhao B, Wu C, Qian S, Shi X, Aplin A, He YY. The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol. 2017 Jul 17. PMID: 28715145.
      Citations:    
    81. Kageyama K, Ohara M, Saito K, Ozaki S, Terai M, Mastrangelo MJ, Fortina P, Aplin AE, Sato T. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis. J Transl Med. 2017 Jun 23; 15(1):145. PMID: 28645290.
      Citations:    
    82. Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH, Alicea GM, Wang J, Ghosh K, Cheng P, Lisanti S, Marchbank K, Dang V, Levesque M, Dummer R, Xu X, Herlyn M, Aplin AE, Roesch A, Caino C, Altieri DC, Weeraratna AT. Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. Clin Cancer Res. 2017 Jun 15; 23(12):3181-3190. PMID: 28232477.
      Citations:    
    83. Chua V, Lapadula D, Randolph C, Benovic JL, Wedegaertner PB, Aplin AE. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma. Mol Cancer Res. 2017 May; 15(5):501-506. PMID: 28223438.
      Citations:    
    84. Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther. 2017 Mar; 16(3):516-528. PMID: 28138035.
      Citations:    
    85. Arnheiter H, Long G, Aplin A, Harris J, Kelsh R. Triple jeopardy for people with albinism. Pigment Cell Melanoma Res. 2016 Sep; 29(5):487. PMID: 27615283.
      Citations:    
    86. Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Res. 2016 Sep 15; 76(18):5455-66. PMID: 27488531.
      Citations:    
    87. Aplin AE. The melanoma field with dendritic roots. Pigment Cell Melanoma Res. 2016 Jul; 29(4):397. PMID: 27320440.
      Citations:    
    88. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 Jul; 29(4):404-16. PMID: 27087480.
      Citations:    
    89. Vu HL, Aplin AE. Targeting mutant NRAS signaling pathways in melanoma. Pharmacol Res. 2016 May; 107:111-6. PMID: 26987942.
      Citations:    
    90. Hartsough EJ, Aplin AE. Of Mice and Melanoma: PDX System for Modeling Personalized Medicine. Clin Cancer Res. 2016 Apr 1; 22(7):1550-2. PMID: 26842234.
      Citations:    
    91. Arnheiter H, Long G, Aplin A, Harris J, Kelsh R. Welcome to the New Year! Pigment Cell Melanoma Res. 2016 Jan; 29(1):3. PMID: 26678867.
      Citations:    
    92. Ozaki S, Vuyyuru R, Kageyama K, Terai M, Ohara M, Cheng H, Manser T, Mastrangelo MJ, Aplin AE, Sato T. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol. 2016 Jan; 186(1):43-56. PMID: 26613897.
      Citations:    
    93. Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. J Invest Dermatol. 2016 Feb; 136(2):453-63. PMID: 26967478.
      Citations:    
    94. Vido MJ, Aplin AE. The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox. J Invest Dermatol. 2015 Oct; 135(10):2355-7. PMID: 26358385.
      Citations:    
    95. Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. Am J Pathol. 2015 Sep; 185(9):2505-22. PMID: 26362718.
      Citations:    
    96. Vu HL, Rosenbaum S, Purwin TJ, Davies MA, Aplin AE. RAC1 P29S regulates PD-L1 expression in melanoma. Pigment Cell Melanoma Res. 2015 Sep; 28(5):590-8. PMID: 26176707.
      Citations:    
    97. Capparelli C, Rosenbaum S, Berger AC, Aplin AE. Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma. J Biol Chem. 2015 Oct 2; 290(40):24267-77. PMID: 26269601.
      Citations:    
    98. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res. 2015 Sep 1; 75(17):3554-67. PMID: 26206558.
      Citations:    
    99. Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. J Biol Chem. 2015 Sep 4; 290(36):21901-14. PMID: 26205821.
      Citations:    
    100. Arnheiter H, Bosenberg M, Aplin A, Kelsh R. The value of thesis advisers. Pigment Cell Melanoma Res. 2015 Jul; 28(4):371. PMID: 26074284.
      Citations:    
    101. Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, Aplin AE. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res. 2015 Jul 1; 75(13):2737-48. PMID: 25952648.
      Citations:    
    102. Kelsh R, Aplin A, Arnheiter H, Bosenberg M. Animal experimentation - questioned again! Pigment Cell Melanoma Res. 2015 May; 28(3):241. PMID: 25865769.
      Citations:    
    103. Shao Y, Le K, Cheng H, Aplin AE. NF-?B Regulation of c-FLIP Promotes TNFa-Mediated RAF Inhibitor Resistance in Melanoma. J Invest Dermatol. 2015 Jul; 135(7):1839-48. PMID: 25751672.
      Citations:    
    104. Arnheiter H, Bosenberg M, Aplin A, Kelsh R. The value of thesis advisers. Pigment Cell Melanoma Res. 2015 Mar; 28(2):125. PMID: 25689505.
      Citations:    
    105. Cheng H, Aplin AE. Game of isoforms: PI3K ß-sparing inhibitor is coming. Pigment Cell Melanoma Res. 2015 Mar; 28(2):133-4. PMID: 25573297.
      Citations:    
    106. Kelsh R, Kos L, Arnheiter H, Aplin A, Bosenberg M. What shall we do this year? Pigment Cell Melanoma Res. 2015 Jan; 28(1):1. PMID: 25510371.
      Citations:    
    107. Zhao B, Shah P, Budanov AV, Qiang L, Ming M, Aplin A, Sims DM, He YY. Sestrin2 Protein Positively Regulates AKT Enzyme Signaling and Survival in Human Squamous Cell Carcinoma and Melanoma Cells. J Biol Chem. 2014 Dec 26; 289(52):35806-14. PMID: 25378405.
      Citations:    
    108. Aplin A, Bosenberg M, Soengas M, Kos L, Arnheiter H, Kelsh R. Unmet needs in melanoma research. Pigment Cell Melanoma Res. 2014 Nov; 27(6):1003. PMID: 25346049.
      Citations:    
    109. Weiss MB, Abel EV, Dadpey N, Aplin AE. FOXD3 Modulates Migration through Direct Transcriptional Repression of TWIST1 in Melanoma. Mol Cancer Res. 2014 Sep; 12(9):1314-23. PMID: 25061102.
      Citations:    
    110. Kugel CH, Hartsough EJ, Davies MA, Setiady YY, Aplin AE. Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. Cancer Res. 2014 Aug 1; 74(15):4122-32. PMID: 25035390.
      Citations:    
    111. Vu HL, Aplin AE. Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma. Mol Cancer Res. 2014 Oct; 12(10):1509-19. PMID: 24962318.
      Citations:    
    112. Kugel CH, Aplin AE. Adaptive resistance to RAF inhibitors in melanoma. Pigment Cell Melanoma Res. 2014 Nov; 27(6):1032-8. PMID: 24828387.
      Citations:    
    113. Hartsough EJ, Basile KJ, Aplin AE. Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-Expressing Melanoma. Mol Cancer Res. 2014 May; 12(5):795-802. PMID: 24520098.
      Citations:    
    114. Basile KJ, Le K, Hartsough EJ, Aplin AE. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014 May; 27(3):479-84. PMID: 24422853.
      Citations:    
    115. Sanchez IM, Aplin AE. Hippo: hungry, hungry for melanoma invasion. J Invest Dermatol. 2014 Jan; 134(1):14-6. PMID: 24352079.
      Citations:    
    116. Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE. In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors. Cancer Res. 2013 Dec 1; 73(23):7101-10. PMID: 24121492.
      Citations:    
    117. Hartsough E, Shao Y, Aplin AE. Resistance to RAF Inhibitors Revisited. J Invest Dermatol. 2014 Feb; 134(2):319-25. PMID: 24108405.
      Citations:    
    118. Hartsough EJ, Aplin AE. A STATement on Vemurafenib-Resistant Melanoma. J Invest Dermatol. 2013 Aug; 133(8):1928-9. PMID: 23856932.
      Citations:    
    119. Le K, Blomain ES, Rodeck U, Aplin AE. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 2013 Jul; 26(4):509-17. PMID: 23490205.
      Citations:    
    120. Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M. Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell Melanoma Res. 2013 Jul; 26(4):E8-E14. PMID: 23531109.
      Citations:    
    121. Abel EV, Basile KJ, Kugel CH, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W, Schuchter LM, Lee JB, Ertel A, Fortina P, Aplin AE. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest. 2013 May 1; 123(5):2155-68. PMID: 23543055.
      Citations:    
    122. Weiss MB, Abel EV, Mayberry MM, Basile KJ, Berger AC, Aplin AE. TWIST1 Is an ERK1/2 Effector That Promotes Invasion and Regulates MMP-1 Expression in Human Melanoma Cells. Cancer Res. 2012 Dec 15; 72(24):6382-92. PMID: 23222305.
      Citations:    
    123. Basile KJ, Aplin AE. Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. Am J Cancer Res. 2012; 2(6):726-35. PMID: 23226618.
      Citations:    
    124. Kaplan FM, Kugel CH, Dadpey N, Shao Y, Abel EV, Aplin AE. SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor. J Biol Chem. 2012 Dec 7; 287(50):41797-807. PMID: 23076151.
      Citations:    
    125. Vu HL, Aplin AE. The Yin-Yang of RAF inhibitors. Pigment Cell Melanoma Res. 2012 Mar; 25(2):127-8. PMID: 22409366.
      Citations:    
    126. Basile KJ, Aplin AE. Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations. Adv Pharmacol. 2012; 65:315-34. PMID: 22959030.
      Citations:    
    127. Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res. 2012 Jan; 25(1):E1-11. PMID: 22117673.
      Citations:    
    128. Aplin AE. Axl of evil? J Invest Dermatol. 2011 Dec; 131(12):2343-5. PMID: 22071539.
      Citations:    
    129. Antin JH, Aplin AE, Cheng SY, Emmert-Buck MR, Cryns VL, Wang D. American journal of cancer research: editorial board (2011). Am J Cancer Res. 2011; 1(6):817-22. PMID: 22016829.
      Citations:    
    130. Abel EV, Aplin AE. Finding the root of the problem: the quest to identify melanoma stem cells. Front Biosci (Schol Ed). 2011; 3:937-45. PMID: 21622243.
      Citations:    
    131. Aplin AE, Kaplan FM, Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol. 2011 Sep; 131(9):1817-20. PMID: 21593776.
      Citations:    
    132. Katiyar P, Aplin AE. FOXD3 regulates migration properties and Rnd3 expression in melanoma cells. Mol Cancer Res. 2011 May; 9(5):545-52. PMID: 21478267.
      Citations:    
    133. Aplin AE, Sato T. Mind the BAP. Pigment Cell Melanoma Res. 2011 Feb; 24(1):6-7. PMID: 21129163.
      Citations:    
    134. Weiss MB, Aplin AE. Paying "particle" attention to novel melanoma treatment strategies. J Invest Dermatol. 2010 Dec; 130(12):2699-701. PMID: 21068733.
      Citations:    
    135. Antin JH, Emmert-Buck MR, Aplin AE, Cheng SY, Cryns VL, Wang D. Launching of American Journal of Cancer Research. Am J Cancer Res. 2011; 1(1):i. PMID: 21969259.
      Citations:    
    136. Trimmer C, Whitaker-Menezes D, Bonuccelli G, Milliman JN, Daumer KM, Aplin AE, Pestell RG, Sotgia F, Lisanti MP, Capozza F. CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Res. 2010 Oct 1; 70(19):7489-99. PMID: 20709760.
      Citations:    
    137. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 2010 Aug 15; 70(16):6670-81. PMID: 20647317.
      Citations:    
    138. Kaplan FM, Mastrangelo MJ, Aplin AE. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. J Invest Dermatol. 2010 Nov; 130(11):2669-71. PMID: 20574441.
      Citations:    
    139. Abel EV, Aplin AE. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. Cancer Res. 2010 Apr 1; 70(7):2891-900. PMID: 20332228.
      Citations:    
    140. Hu R, Aplin AE. alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells. Pigment Cell Melanoma Res. 2010 Apr; 23(2):201-9. PMID: 20067552.
      Citations:    
    141. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE. Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res. 2009 Apr; 7(4):549-56. PMID: 19372583.
      Citations:    
    142. Klein RM, Aplin AE. Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res. 2009 Mar 15; 69(6):2224-33. PMID: 19244113.
      Citations:    
    143. Hu R, Aplin AE. Skp2 regulates G2/M progression in a p53-dependent manner. Mol Biol Cell. 2008 Nov; 19(11):4602-10. PMID: 18716061.
      Citations:    
    144. Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE. B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell. 2008 Feb; 19(2):498-508. PMID: 18045987.
      Citations:    
    145. Carlson JA, Linette GP, Aplin A, Ng B, Slominski A. Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin. 2007 Oct; 25(4):541-57, viii-ix. PMID: 17903613.
      Citations:    
    146. Chen C, Seth AK, Aplin AE. Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer. Mol Cancer Res. 2006 Oct; 4(10):695-707. PMID: 17050664.
      Citations:    
    147. Spofford LS, Abel EV, Boisvert-Adamo K, Aplin AE. Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression. J Biol Chem. 2006 Sep 1; 281(35):25644-51. PMID: 16815849.
      Citations:    
    148. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene. 2005 May 12; 24(21):3459-71. PMID: 15735667.
      Citations:    
    149. Connor KM, Subbaram S, Regan KJ, Nelson KK, Mazurkiewicz JE, Bartholomew PJ, Aplin AE, Tai YT, Aguirre-Ghiso J, Flores SC, Melendez JA. Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem. 2005 Apr 29; 280(17):16916-24. PMID: 15701646.
      Citations:    
    150. Conner SR, Scott G, Aplin AE. Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J Biol Chem. 2003 Sep 5; 278(36):34548-54. PMID: 12821662.
      Citations:    
    151. Aplin AE. Cell adhesion molecule regulation of nucleocytoplasmic trafficking. FEBS Lett. 2003 Jan 16; 534(1-3):11-4. PMID: 12527355.
      Citations:    
    152. Aplin AE, Hogan BP, Tomeu J, Juliano RL. Cell adhesion differentially regulates the nucleocytoplasmic distribution of active MAP kinases. J Cell Sci. 2002 Jul 1; 115(Pt 13):2781-90. PMID: 12077368.
      Citations:    
    153. Howe AK, Aplin AE, Juliano RL. Anchorage-dependent ERK signaling--mechanisms and consequences. Curr Opin Genet Dev. 2002 Feb; 12(1):30-5. PMID: 11790551.
      Citations:    
    Aplin's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (247)
    Explore
    _
    Co-Authors (50)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _